Modeling disease progression through multiple stages is critical for clinical decision-making for chronic diseases, e.g., cancer, diabetes, chronic kidney diseases, and so on. Existing approaches often model the disease progression as a uniform trajectory pattern at the population level. However, chronic diseases are highly heterogeneous and often have multiple progression patterns depending on a patient's individual genetics and environmental effects due to lifestyles. We propose a personalized disease progression model to jointly learn the heterogeneous progression patterns and groups of genetic profiles. In particular, an end-to-end pipeline is designed to simultaneously infer the characteristics of patients from genetic markers using a variational autoencoder and how it drives the disease progressions using an RNN-based state-space model based on clinical observations. Our proposed model shows improvement on real-world and synthetic clinical data.

Drug discovery is a complex, multi-stage process. Lead identification and lead optimization remain costly with low success-rates and computational methods play an important role in accelerating these tasks [1-3]. The prediction of a broad range of chemical and biological properties of candidate molecules is an essential component of screening and assessing molecules and data-driven, machine learning approaches have long aided in this process [4-6]. Molecular representations form the basis of machine learning models [2, 7], facilitating algorithmic and scientific advances in the field. However, learning useful and generalized latent representation is a hard problem due to limited amounts of labeled data, wide ranges of downstream tasks, vast chemical space, and large heterogeneity in molecular structures. Learning latent representations using unsupervised techniques is vital for such models to scale. Large language models (LLMs) have revolutionized other fields [8] and similar sequence-based foundation models have shown promise to learn molecular representations and be trainable on many downstream property prediction tasks [9-11]. A key advantage is that the transformer based architecture can learn in a self-supervised fashion to create a "pre-trained" molecular representation. The most direct application of LLM like transformers is facilitated by a sequence, text-based representation (e.g.

Primary care professionals struggle to keep up to date with the latest scientific literature critical in guiding evidence-based practice related to their daily work. To help solve the above-mentioned problem, we employed generative artificial intelligence techniques based on large-scale language models to summarize abstracts of scientific papers. Our objective is to investigate the potential of generative artificial intelligence in diminishing the cognitive load experienced by practitioners, thus exploring its ability to alleviate mental effort and burden. The study participants were provided with two use cases related to preventive care and behavior change, simulating a search for new scientific literature. The study included 113 university students from Slovenia and the United States randomized into three distinct study groups. The first group was assigned to the full abstracts. The second group was assigned to the short abstracts generated by AI. The third group had the option to select a full abstract in addition to the AI-generated short summary. Each use case study included ten retrieved abstracts. Our research demonstrates that the use of generative AI for literature review is efficient and effective. The time needed to answer questions related to the content of abstracts was significantly lower in groups two and three compared to the first group using full abstracts. The results, however, also show significantly lower accuracy in extracted knowledge in cases where full abstract was not available. Such a disruptive technology could significantly reduce the time required for healthcare professionals to keep up with the most recent scientific literature; nevertheless, further developments are needed to help them comprehend the knowledge accurately.

Medical experts may use Artificial Intelligence (AI) systems with greater trust if these are supported by contextual explanations that let the practitioner connect system inferences to their context of use. However, their importance in improving model usage and understanding has not been extensively studied. Hence, we consider a comorbidity risk prediction scenario and focus on contexts regarding the patients clinical state, AI predictions about their risk of complications, and algorithmic explanations supporting the predictions. We explore how relevant information for such dimensions can be extracted from Medical guidelines to answer typical questions from clinical practitioners. We identify this as a question answering (QA) task and employ several state-of-the-art LLMs to present contexts around risk prediction model inferences and evaluate their acceptability. Finally, we study the benefits of contextual explanations by building an end-to-end AI pipeline including data cohorting, AI risk modeling, post-hoc model explanations, and prototyped a visual dashboard to present the combined insights from different context dimensions and data sources, while predicting and identifying the drivers of risk of Chronic Kidney Disease - a common type-2 diabetes comorbidity. All of these steps were performed in engagement with medical experts, including a final evaluation of the dashboard results by an expert medical panel. We show that LLMs, in particular BERT and SciBERT, can be readily deployed to extract some relevant explanations to support clinical usage. To understand the value-add of the contextual explanations, the expert panel evaluated these regarding actionable insights in the relevant clinical setting. Overall, our paper is one of the first end-to-end analyses identifying the feasibility and benefits of contextual explanations in a real-world clinical use case.

Artificial intelligence, and particularly machine learning (ML), is increasingly developed and deployed to support healthcare in a variety of settings. However, clinical decision support (CDS) technologies based on ML need to be portable if they are to be adopted on a broad scale. In this respect, models developed at one institution should be reusable at another. Yet there are numerous examples of portability failure, particularly due to naive application of ML models. Portability failure can lead to suboptimal care and medical errors, which ultimately could prevent the adoption of ML-based CDS in practice. One specific healthcare challenge that could benefit from enhanced portability is the prediction of 30-day readmission risk. Research to date has shown that deep learning models can be effective at modeling such risk. In this work, we investigate the practicality of model portability through a cross-site evaluation of readmission prediction models. To do so, we apply a recurrent neural network, augmented with self-attention and blended with expert features, to build readmission prediction models for two independent large scale claims datasets. We further present a novel transfer learning technique that adapts the well-known method of born-again network (BAN) training. Our experiments show that direct application of ML models trained at one institution and tested at another institution perform worse than models trained and tested at the same institution. We further show that the transfer learning approach based on the BAN produces models that are better than those trained on just a single institution's data. Notably, this improvement is consistent across both sites and occurs after a single retraining, which illustrates the potential for a cheap and general model transfer mechanism of readmission risk prediction.